Safety of biologics: Current issues and future concerns

Acta Gastro-Enterologica Belgica

Volumn 64, Issue 2, 2001, Pages 210-214

  Feagan, B G ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY;

CHRONIC INFLAMMATION; COLON CROHN DISEASE; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG USE; FUTUROLOGY; HUMAN;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; CROHN DISEASE; HUMANS; SAFETY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034933391     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. TARGAN S.R., HANAUER S.B., VAN DEVENTER S.J. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease. N. Engl. J. Med., 1997, 337 : 1029-1035.
2. PRESENT D.H., RUTGEERTS P., TARGAN S. et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med., 1999, 340: 1398-1405.
3. EDWARDS I.R., ARONSON J.K. Adverse drug reactions : Definitions, diagnosis, and management. Lancet, 2000, 356 (9237) : 1255-1259.
4. SACKETT D., HAYNES R.B., TUGWELL P. Clinical Epidemiology : A Basic Science for Clinical Medicine. Little, Brown and Company, 1985.
5. IBRAHIM M.A. The case-control study : Consensus and controversy. J. Chronic Dis., 1979, 132 : 1.
6. SACKETT D.L. Bias in analytic research. J. Chronic Dis., 1979, 32 : 51-63.
7. United States Food and Drug Administration. Glaxo Wellcome decides to withdraw Lotronex from the market. PDA Homepage. 2000.
8. BICKSTON S.J., LICHTENSTEIN G.R., ARSENEAU K.O., COHEN R.B., COMINELLI F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology, 1999, 117 : 1433-1437.
9. MINOR P.D. Mammalian cells and their contaminants. Dev. Biol. Stand., 1996, 88 : 25-29.
10. THOMSON B.J., DORAN M., LEVER A.M., WEBSTER A.D. Alpha-Interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet, 1987, 1 (8532) : 539-541.
11. HILLEMAN M.R. Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Dev. Biol. Stand., 1998, 94 : 183-190.
12. STACK W.A., MANN S.D., ROY A.J. et al. Randomized controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet, 1997, 349: 521-524.